Elevated CSN6 may be prognostic for poor survival colorectal cancer
the ONA take:
A study from The University of Texas MD Anderson Cancer Center identified a protein, CSN6, a subunit of a protein complex known as COP9 signalsome, that correlated with poor survival in patients with colorectal cancer. The researchers found that elevated CSN6 is a biomarker for worse recurrence-free survival in patients with colon cancer.
CSN6 is normally regulated through the EGFR and ERK signaling pathways. When overexpressed via ERK2 in particular, it leads to deregulation of beta-catenin, a transcription factor known to be linked to cancer development.
The current standard of treatment for colorectal cancer in patients at high risk of recurrent or metastatic disease includes surgery, chemotherapy, and targeted therapies.
The researchers report that defining the molecular alterations can help guide treatment and improve clinical care.
CSN6, a subunit of a protein complex known as COP9 signalsome, correlated with poor survival in patients with colorectal cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|